# Context Therapeutics Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Context Therapeutics Inc.).

## Overview

Context Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapy product candidates for cancer. Its pipeline includes CTIM-76, CT-95 and CT-202, and the company is currently focused on advancing these assets through preclinical work and early-stage clinical trials while seeking regulatory approval and future commercialization.

## Products & services

• CTIM-76 oncology product candidate
• CT-95 immunotherapy product candidate
• CT-202 (BA3362) Nectin-4 x CD3 TCE bispecific antibody
• Preclinical and Phase 1 clinical development
• Manufacturing, regulatory and commercialization planning

- **Clinical-stage product candidates** (0%) — Includes CTIM-76, CT-95 and CT-202 being advanced through nonclinical and early clinical development.
- **Research and development services** (100%) — Internal discovery, preclinical testing, clinical trial execution and regulatory preparation for pipeline assets.
- **Licensing and asset acquisition** (0%) — In-licensed or acquired programs and related intellectual property, know-how and regulatory assets.

- CTIM-76 oncology product candidate
- CT-95 immunotherapy product candidate
- CT-202 (BA3362) Nectin-4 x CD3 TCE bispecific antibody
- Preclinical and Phase 1 clinical development
- Manufacturing, regulatory and commercialization planning

## Customers

Context Therapeutics does not yet sell approved products; its current 'customers' are primarily clinical trial sites, investigators, CROs and manufacturing partners that support development. If its candidates are approved, the end buyers would be oncology physicians, hospitals and cancer treatment centers using the therapies for patients with solid tumors.

- **Clinical development partners** (primary) — CROs, investigators and trial sites that execute preclinical studies and Phase 1 trials for CTIM-76, CT-95 and CT-202.
- **Manufacturing and supply chain partners** (primary) — Contract manufacturers and suppliers that provide drug substance, drug product and clinical trial materials.
- **Future oncology treatment providers** (emerging) — Hospitals, cancer centers and physicians that would prescribe approved therapies to patients with cancer.
- **Strategic licensing counterparties** (secondary) — Biotech licensors and collaborators that provide assets, IP or development rights to expand the pipeline.

- Clinical trial sites enrolling patients in Phase 1 studies
- CROs and investigators supporting preclinical and clinical work
- Manufacturing and supply partners producing clinical material
- Future oncology physicians and hospitals if products are approved
- Potential licensing or collaboration partners for pipeline assets

## Geography

The company is headquartered in the United States and its development and financing activities are centered there. Its CT-95 patent estate is being prosecuted or maintained across the United States, Europe, Canada, Australia, Japan and Taiwan, reflecting a global intellectual property footprint even though the business remains pre-revenue.

- Headquartered in the United States
- Clinical and corporate operations are U.S.-centric
- CT-95 IP is prosecuted in the U.S., Europe, Canada, Australia, Japan and Taiwan
- CT-202 is licensed worldwide from BioAtla
- No country revenue disclosure because the company has no product sales

## Strategy

Context Therapeutics is prioritizing advancement of its lead pipeline assets through early clinical development while building the manufacturing, regulatory and IP foundation needed for later-stage trials. A second priority is financing: the company expects to fund operations through equity, debt, collaborations and licensing until product revenue, if any, is available.

- **Advance the lead pipeline through Phase 1 and first-in-human studies** (short-term) — Clinical proof-of-concept is the main value driver for a pre-revenue biotech company.
- **Secure additional financing and extend cash runway** (short-term) — The company has no product revenue and needs capital to fund R&D and operations.
- **Build manufacturing and regulatory capabilities** (medium-term) — Clinical supply and eventual commercialization require scalable external manufacturing and regulatory execution.
- **Expand and defend intellectual property** (medium-term) — Patent protection is central to exclusivity, partnering leverage and eventual commercial value.

- Advance CTIM-76, CT-95 and CT-202 through early clinical stages
- Scale external manufacturing capacity for clinical and future commercial supply
- Protect and expand intellectual property around pipeline assets
- Use collaborations and licensing to extend runway and de-risk development
- Raise additional capital through equity, debt or strategic transactions

## Risks

The company is highly exposed to clinical, financing and intellectual property risk because it has no approved products and depends on successful development outcomes. Regulatory delays, patent disputes, manufacturing constraints and the need for repeated capital raises could materially affect its ability to continue operations and advance the pipeline.

- **Financing risk** [high] — The company expects to need substantial additional capital and has no committed credit facility.
- **Clinical development failure** [high] — Pipeline value depends on successful preclinical and Phase 1 results for CTIM-76, CT-95 and CT-202.
- **Intellectual property litigation** [high] — Third parties may assert patent claims or challenge the company’s rights to use key technology.
- **Regulatory delay risk** [medium] — FDA and broader U.S. regulatory changes can slow approvals and increase compliance burden.
- **Supply chain and tariff risk** [medium] — Imported raw materials and clinical supplies may become more expensive or harder to source.

- No product revenue; success depends on clinical and regulatory outcomes
- Additional financing will likely be required before commercialization
- Patent disputes could delay or block development and sales
- Clinical trial timing can cause large swings in expenses and losses
- Trade policy and FDA changes may disrupt supply or approval timelines

## Accounting

Context Therapeutics is a pre-revenue biotech, so reported results are driven mainly by R&D expense timing, G&A overhead and noncash share-based compensation rather than product sales. Investors should watch how milestone payments, in-licensed asset costs, clinical trial accruals and future impairment or valuation judgments affect the income statement and balance sheet.

- **Research and development expense recognition** — Quarterly results can fluctuate materially with trial activity and vendor accruals.
- **Clinical trial accrual estimates** — Accrual changes can move operating expenses and liabilities.
- **License and asset acquisition accounting** — Affects balance sheet assets, expense recognition and future impairment risk.
- **Share-based compensation** — Raises G&A and R&D expense without immediate cash outflow.
- **Emerging growth company accounting** — Financial statements may not be directly comparable to non-EGC biotech companies.

- R&D expense timing drives quarter-to-quarter loss volatility
- Clinical trial accruals depend on estimates for CRO and site costs
- License and asset purchase payments may create intangible or expense recognition issues
- Share-based compensation is meaningful for a public biotech
- Future milestone obligations and royalties affect cash needs and disclosures

---

*Last updated: 2026-04-28T19:59:04.202417+00:00*